4.39

0.68% -0.03

Psyence Biomedical Ltd (PBM)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$4.42

Offen:

$4.29

24-Stunden-Volumen:

26,345

Relative Volume:

0.40

Marktkapitalisierung:

$2.50M

Einnahmen:

Nettoeinkommen (Verlust:

KGV:

EPS:

Netto-Cashflow:

1W Leistung:

-15.58%

1M Leistung:

+20.58%

6M Leistung:

-83.12%

1J Leistung:

-99.11%

1-Tages-Spanne:

$4.28

$4.505

1-Wochen-Bereich:

$4.2438

$7.69

52-Wochen-Spanne:

$2.9218

$699.19

Psyence Biomedical Ltd Stock (PBM) Company Profile

Firmenname

Psyence Biomedical Ltd

Sektor

Healthcare (1173)

Branche

Biotechnology (666)

Telefon

Adresse

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

PBM's Discussions on Twitter

Vergleichen Sie PBM mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PBM Psyence Biomedical Ltd	4.39	3.03M	0	0	0	0.00
ONC Beigene Ltd Adr	241.43	27.03B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	436.00	112.64B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.335	40.86M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	588.34	64.17B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	75.06	6.07B	0	-153.72M	-103.81M	-2.00

Psyence Biomedical Ltd Aktie (PBM) Neueste Nachrichten

May 20, 2025

Psyence Biomedical Advances Psilocybin Drug Development as of May 2025 - TipRanks

May 20, 2025

May 08, 2025

Reviewing Psyence Biomedical (NASDAQ:PBM) and Immunic (NASDAQ:IMUX) - Defense World

May 08, 2025

May 02, 2025

Psyence Biomedical announces reverse stock split - Investing.com

May 02, 2025

May 01, 2025

Psyence Biomedical announces reverse stock split By Investing.com - Investing.com Nigeria

May 01, 2025

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split - Newsfile

May 01, 2025

Psyence BioMed Reverse Split Cuts 4.6M Shares to 583K: What Investors Must Know Before May 5 - Stock Titan

May 01, 2025

Apr 23, 2025

Psyence Biomedical Faces Nasdaq Delisting Amid Shareholder Approval for Reverse Stock Split - TipRanks

Apr 23, 2025

Apr 20, 2025

Psyence BioMed gets Nasdaq notice for non-compliance - MSN

Apr 20, 2025

Apr 18, 2025

Psyence Group consolidates its shares - Crain's Chicago Business

Apr 18, 2025

Apr 17, 2025

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - TradingView

Apr 17, 2025

Apr 16, 2025

Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine

Apr 16, 2025

Apr 15, 2025

Psyence BioMed boosts stake in PsyLabs with $500k investment By Investing.com - Investing.com Nigeria

Apr 15, 2025

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement - Newsfile

Apr 15, 2025

Apr 11, 2025

Psyence Biomedical Transitions CRO for Psilocybin Trial in April 2025 - TipRanks

Apr 11, 2025

Apr 08, 2025

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia - Newsfile

Apr 08, 2025

Major Expansion: Psyence's Breakthrough Cancer Mental Health Trial Targets Untreated Disorder - Stock Titan

Apr 08, 2025

Apr 02, 2025

Psyence Biomedical reports corporate update By Investing.com - Investing.com Australia

Apr 02, 2025

Apr 01, 2025

Psyence Biomedical reports corporate update - Investing.com

Apr 01, 2025

Psyence BioMed Advances in Psychedelic Medicine with Strategic Growth and Clinical Trials - TipRanks

Apr 01, 2025

Mar 31, 2025

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing - TradingView

Mar 31, 2025

Psyence Biomedical Announces Special Shareholder Meeting for Share Consolidation - TipRanks

Mar 31, 2025

Mar 25, 2025

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein - The Manila Times

Mar 25, 2025

Mar 21, 2025

Psyence Biomedical Ltd. (NASDAQ:PBMWW) Short Interest Down 13.1% in February - Defense World

Mar 21, 2025

Mar 19, 2025

Psyence Biomed expands advisory board with psychopharmacology expert By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 18, 2025

Psyence Biomed expands advisory board with psychopharmacology expert - Investing.com India

Mar 18, 2025

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein - Newsfile

Mar 18, 2025

Top Columbia Psychiatrist Joins Psyence's Psilocybin Clinical Trial Team - StockTitan

Mar 18, 2025

Mar 10, 2025

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - The Manila Times

Mar 10, 2025

Mar 06, 2025

Psyence Biomedical files to sell 13.81M common shares for holders - MSN

Mar 06, 2025

Mar 04, 2025

Psyence Biomedical Ltd Files For Mixed Shelf Of Up To $75LN -March 04, 2025 at 04:48 pm EST - Marketscreener.com

Mar 04, 2025

Psyence Biomedical Ltd Files For Mixed Shelf Of Up To $75LN - TradingView

Mar 04, 2025

Feb 26, 2025

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - GlobeNewswire

Feb 26, 2025

Can This Johns Hopkins Psychedelics Expert Accelerate Psyence's Psilocybin Breakthroughs? - StockTitan

Feb 26, 2025

Feb 07, 2025